Former LifeMD staff say company pushed rapid GLP-1 prescriptions at expense of patient safety

Former employees of telehealth firm LifeMD allege the company encouraged clinicians to see more patients and issue weight‑loss drug prescriptions quickly, with limited screening or follow‑up.

Five ex‑workers described the pressure in interviews, and two former senior leaders have filed lawsuits claiming the practice puts patients at risk.

LifeMD, which has been highlighted by Novo Nordisk as a partner in expanding access to GLP‑1 therapies, denies the accusations and says its prescribing protocols meet all applicable standards.

Industry observers warn that the growing number of telehealth platforms offering obesity treatments could lead to lax clinical oversight, potentially increasing safety concerns for patients.